Clinical trials: RNA Virus Infections
Japanese Encephalitis
Post-licensure Safety Study of IMOJEV® in Thailand
The aim of this study is to further characterize the safety profile of IMOJEV®. Primary Objective: To describe serious adverse events (SAEs, including adverse events of special interest [AESIs]) up to 60 days after administration…
- Trial name
- NCT01981967
- Testing
- IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine
- Where
- 8 sites in Thailand
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Yellow Fever
Trial of an Inactivated Yellow Fever Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 1 mcg and 5 mcg of HydroVax-002 YFV vaccine given intramuscularly on Day 1 and Day 29…
- Trial name
- NCT05172544
- Testing
- HydroVax-002 YFV
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Najit Technologies, Inc.
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease
Sonoelastography: Ultrasound Method to Measure Liver Fibrosis
HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) will provide accurate quantitative measurements that can be used to stage liver fibrosis in patients with chronic liver disease. 1.
- Conditions
- Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV)
- Trial name
- NCT01747772
- Testing
- Shear Wave Sonoelastography
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Massachusetts General Hospital
Common Cold
Effect of Paracetamol on the Common Cold
The aim of this study is to subjectively assess symptoms in subjects suffering from the common cold following a single dose of paracetamol hot drink compared to paracetamol tablet
- Trial name
- NCT01277081
- Testing
- Paracetamol hot drink, Paracetamol tablets
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Coronavirus, Convalescence
Convalescent Plasma to Stem Coronavirus (CSSC-001)
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
- Trial name
- CSSC-001 (NCT04323800)
- Testing
- Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma
- Where
- 25 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
COVID-19
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.
- Trial name
- NCT04315298
- Testing
- Sarilumab
- Where
- 62 sites in United States
- Volunteers
- 1,912 people
- Sponsor
- Regeneron Pharmaceuticals
Pertussis, Diphtheria
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
Post-marketing evaluation of reactions following receipt of recommended adolescent pertussis vaccine among persons with prior vaccination with acellular vs whole-cell pertussis vaccine.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00304265
- Testing
- COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)
- Where
- 17 sites in Germany
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV Infections
A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
The investigators hypothesize that following virological failure of a standard NNRTI+2N(T)RTI regimen second-line antiretroviral therapy consisting of ritonavir-boosted lopinavir and 2N(T)RTIs will offer comparable efficacy to…
- Trial name
- SECOND-LINE (NCT00931463)
- Testing
- raltegravir, 2N(t)RTI, Ritonavir-boosted lopinavir
- Where
- 44 sites in Argentina, Australia and 15 more
- Volunteers
- 558 people
- Sponsor
- Kirby Institute
Covid19
Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease.
- Trial name
- COPS-2003 (NCT04524663)
- Testing
- Camostat Mesilate, Standard of Care Treatment
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Stanford University
HIV Infections, Viremia
Enhanced Virologic Monitoring for Pregnant and Postpartum Women With HIV
The goal of this study is to learn about supporting pregnant and postpartum women living with HIV with treatment adherence. The investigators will conduct a pilot study of an intervention that includes peer counseling about viral…
- Conditions
- HIV Infections, Viremia, Pregnancy Related
- Trial name
- NCT05845619
- Testing
- Enhanced virologic monitoring
- Where
- 4 sites in Kenya
- Volunteers
- 550 people
- Sponsor
- University of California, San Francisco
HIV, HIV Infections
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
The objective of this double-blinded, multicenter, randomized, active-controlled study is to evaluate the safety and efficacy of Stribild, a single-tablet regimen (STR) containing fixed doses of elvitegravir (EVG)/GS-9350…
- Trial name
- NCT00869557
- Testing
- Stribild, Atripla
- Where
- 30 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
The purpose of this study is to assess the safety and efficacy of daclatasvir and simeprevir with and without ribavirin for genotype 1 chronic hepatitis C virus infection in patients who are treatment-naive or null responders to…
- Trial name
- NCT01628692
- Testing
- Daclatasvir, Simeprevir, Ribavirin
- Where
- 26 sites in United States, Argentina and 4 more
- Volunteers
- 230 people
- Sponsor
- Bristol-Myers Squibb
HIV
BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.
The purpose of this Phase IV pilot study is to evaluate the safety, tolerability, and satisfaction of a nucleoside analog reverse-transcriptase inhibitors (NRTI)sparing regimen for participants fully suppressed on an…
- Trial name
- BATAR (NCT00931801)
- Testing
- atazanavir/raltegravir, atazanavir/tenofovir/emtricitabine
- Where
- 9 sites in United States
- Volunteers
- 43 people
- Sponsor
- Community Research Initiative of New England
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) with and without ribavirin (RBV) for 12 weeks and SOF/VEL FDC for 24…
- Trial name
- ASTRAL-4 (NCT02201901)
- Testing
- SOF/VEL, RBV
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 268 people
- Sponsor
- Gilead Sciences
Hepatitis B, Polio
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule The primary objective is to demonstrate that the hexavalent DTaP-IPV-HB-PRP~T…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00362336
- Testing
- DTaP-IPV-HB-PRP~T, CombAct-HIB®, Engerix B® Pediatric
- Where
- 2 sites in South Africa
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV Infections
Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults
The purpose of this study is to determine the effectiveness of minocycline, an antibiotic, in lessening the decreased mental function sometimes caused by anti-HIV drugs.
- Trial name
- NCT00361257
- Testing
- Minocycline
- Where
- 16 sites in United States
- Volunteers
- 107 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Influenza
Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)
The primary purpose of the study is to assess the equivalence of the immune response elicited by two GSK Biologicals' adjuvanted influenza investigational vaccines (GSK2340272A and GSK2340274A) in adults aged 18 to 60 years.
- Trial name
- NCT00979407
- Testing
- Influenza vaccine GSK2340272A, Influenza vaccine GSK2340274A
- Where
- 7 sites in France, Germany
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hiv, Opioid-use Disorder
Integrating Addiction Treatment and HIV Services Into Primary Care Clinics in Ukraine
A randomized controlled trial to: 1. To compare both primary (composite quality health indicator (QHI) scores) and secondary (individual HIV/methadone maintenance treatment (MMT)/TB/primary care QHI scores, quality of life, and…
- Trial name
- IMPACT (NCT04927091)
- Testing
- Integration of HIV and PWID services
- Where
- Ukraine
- Volunteers
- 1,590 people
- Sponsor
- Yale University
Influenza A, Influenza B
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B.
- Trial name
- IRC002 (NCT01052480)
- Testing
- Anti-Influenza Immune Plasma, Standard Care
- Where
- 35 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CKD
Home-based Kidney Care in Native Americans of New Mexico (HBKC) - Enhancement: COVID-19 Study
Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) OR COVID-19 related Addition: The aim of this addition activity is to track the impact of the COVID-19 epidemic on participants with diabetes and chronic kidney…
- Trial name
- NCT04520191
- Where
- United States
- Volunteers
- 309 people
- Sponsor
- University of New Mexico
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.